Business
Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference
LA JOLLA, Calif.--(BUSINESS WIRE)-- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat
About this update from Equillium, Inc.
[{"type":"text","content":" LA JOLLA, Calif.--(BUSINESS WIRE)--\nEquillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference, and the LD Micro Invitational Conference.\n\n\nManagement will provide an overview of the company’s clinical programs, partnership with Ono Pharmaceutical and 2024 milestones, during both conferences. Management will also be available for one-on-one meetings during the conferences.\n\n\nConference: H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference\nLocation: Virtual Fireside Chat\nDate: Thursday, March 28\nTime: 11:00 am Pacific Time | 2:00 pm Eastern Time\n\n\nWebcast access will be available on the “Events & Presentations” page under the Investor Relations tab on the Company’s website at https://www.equilliumbio.com/investors/events-and-presentations/default.aspx. An archived replay of the conference will be available for 90 days.\n\n\nConference: LD Micro Invitational\nLocation: Sofitel, New York, NY\nDate: Tuesday, April 9\nTime: 6:30 am Pacific Time | 9:30 am Eastern Time\n\n\nThe presentation at the LD Micro conference will be live-streamed on the event website at https://ldinv14.sequireevents.com/. To access, click ‘Register to Watch’ and then navigate to Equillium presentation. An archived replay of the conference will be available for 30 days.\n\n\nAbout Equillium\n\n\nEquillium is a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The company’s pipeline consists of the following novel first-in-class immunomodulatory assets and product platform targeting immuno-inflammatory pathways. EQ101: a selective tri-specific cytokine inhibitor targeting IL-2, IL-9, and IL-15; currently under evaluation in a Phase 2 proof-of-concept clinical study of patients with alopecia areata being conducted in Australia and New Zealand by Equillium’s Australian subsidiary as the trial sponsor. EQ302: an orally delivered, selective bi-specific cytokine inhibitor targeting IL-15 and IL-21; currently in pre-clinical development. The multi-cytokine platform: generates ...